Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: A microCT study

Arthritis Research and Therapy

Volumn 15, Issue 5, 2013, Pages

  Marenzana, Massimo ^a,b   Vugler, Alex ^a   Moore, Adrian ^a   Robinson, Martyn ^a  

^a UCB PHARMA   (Belgium)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

bone loss; collagen induced arthritis; focal erosion; inflammation; micro computed tomography; microCT; rheumatoid arthritis; Sclerostin; sclerostin antibody

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; NEUTRALIZING ANTIBODY; PHOSPHATE BUFFERED SALINE; SCLEROSTIN; COLLAGEN TYPE 2; GLYCOPROTEIN; IMMUNOGLOBULIN G; SOST PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANKLE; ARTICLE; BONE; BONE DENSITY; BONE EROSION; BONE MASS; BONE STRUCTURE; CONTROLLED STUDY; CORTICAL BONE; CORTICAL THICKNESS (BONE); DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; INFLAMMATION; KNEE; MALE; METAPHYSIS; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOLYSIS; RHEUMATOID ARTHRITIS; TRABECULAR BONE; VERTEBRA BODY; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; DBA MOUSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL ARTHRITIS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; RADIOGRAPHY;

ANIMALS; ANKLE JOINT; ANTIBODIES, NEUTRALIZING; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE AND BONES; BONE DENSITY; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; KNEE JOINT; MALE; MICE; MICE, INBRED DBA; X-RAY MICROTOMOGRAPHY;

EID: 84884189895     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4305     Document Type: Article

References (29)

1. Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 2012, 11:234-250. 10.1038/nrd3669, 22378270.
2. Sinigaglia L, Varenna M, Girasole G, Bianchi G. Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am 2006, 32:631-658. 10.1016/j.rdc.2006.07.002, 17288969.
3. McLean RR. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep 2009, 7:134-139. 10.1007/s11914-009-0023-2, 19968917.
4. Roux C. Osteoporosis in inflammatory joint diseases. Osteoporos Int 2011, 22:421-433.
5. Polzer K, Diarra D, Zwerina J, Schett G. Inflammation and destruction of the joints--the Wnt pathway. Joint Bone Spine 2008, 75:105-107. 10.1016/j.jbspin.2007.10.005, 18313347.
6. Rabelo F de S, da Mota LMH, Lima RAC, Lima FAC, Barra GB, de Carvalho JF, Amato AA. The Wnt signaling pathway and rheumatoid arthritis. Autoimmun Rev 2010, 9:207-210. 10.1016/j.autrev.2009.08.003, 19683077.
7. Nakamura Y, Nawata M, Wakitani S. Expression profiles and functional analyses of Wnt-related genes in human joint disorders. Am J Pathol 2005, 167:97-105. 10.1016/S0002-9440(10)62957-4, 1603448, 15972956.
8. Sen M, Chamorro M, Reifert J, Corr M, Carson DA. Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis Rheum 2001, 44:772-781. 10.1002/1529-0131(200104)44:4<772::AID-ANR133>3.0.CO;2-L, 11315916.
9. Sen M, Reifert J, Lauterbach K, Wolf V, Rubin JS, Corr M, Carson DA. Regulation of fibronectin and metalloproteinase expression by Wnt signaling in rheumatoid arthritis synoviocytes. Arthritis Rheum 2002, 46:2867-2877. 10.1002/art.10593, 12428226.
10. Tanaka I, Morikawa M, Okuse T, Shirakawa M, Imai K. Expression and regulation of WISP2 in rheumatoid arthritic synovium. Biochem Biophys Res Commun 2005, 334:973-978. 10.1016/j.bbrc.2005.06.196, 16038875.
11. Garnero P, Tabassi NC-B, Voorzanger-Rousselot N. Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. J Rheumatol 2008, 35:2313-2315. 10.3899/jrheum.080356, 18843784.
12. Wang S-Y, Liu Y-Y, Ye H, Guo J-P, Li R, Liu X, Li Z-G. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol 2011, 38:821-827. 10.3899/jrheum.100089, 21362762.
13. Heiland GR, Zwerina K, Baum W, Kireva T, Distler JH, Grisanti M, Asuncion F, Li X, Ominsky M, Richards W, Schett G, Zwerina J. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 2010, 69:2152-2159. 10.1136/ard.2010.132852, 20858621.
14. Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB, Gravallese EM. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 2009, 24:1572-1585. 10.1359/jbmr.090320, 19338457.
15. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163. 10.1038/nm1538, 17237793.
16. Paszty C, Turner CH, Robinson MK. Sclerostin: a gem from the genome leads to bone-building antibodies. J Bone Miner Res 2010, 25:1897-1904. 10.1002/jbmr.161, 20564241.
17. Eddleston A, Marenzana M, Moore AR, Stephens P, Muzylak M, Marshall D, Robinson MK. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 2009, 24:1662-1671. 10.1359/jbmr.090403, 19419292.
18. Bolon B, Stolina M, King C, Middleton S, Gasser J, Zack D, Feige U. Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy. J Biomed Biotechnol 2011, 2011:569068. 3022224, 21253435.
19. Hegen M, Keith JC, Collins M, Nickerson-Nutter CL. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis 2008, 67:1505-1515. 10.1136/ard.2007.076430, 18055474.
20. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980, 283:666-668. 10.1038/283666a0, 6153460.
21. Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, Robinson MK. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum 2011, 63:2385-2395. 10.1002/art.30385, 21484764.
22. Stok KS, Noël D, Apparailly F, Gould D, Chernajovsky Y, Jorgensen C, Müller R. Quantitative imaging of cartilage and bone for functional assessment of gene therapy approaches in experimental arthritis. J Tissue Eng Regen Med 2010, 4:387-394. 10.1002/term.251, 20101620.
23. Confavreux CB, Chapurlat RD. Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis. Osteoporos Int 2011, 22:1023-1036. 10.1007/s00198-010-1462-4, 20959960.
24. Roudier M, Li X, Niu Q-T, Pacheco E, Pretorius J, Graham K, Yoon B-RP, Gong J, Warmington K, Ke HZ, Black RA, Hulme J, Babij P. Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury. Arthritis Rheum 2012, 65:721-31.
25. Chen X-X, Baum W, Dwyer D, Stock M, Schwabe K, Ke H-Z, Stolina M, Schett G, Bozec A. Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann Rheum Dis 2013
26. Le Goff B, Soltner E, Charrier C, Maugars Y, Rédini F, Heymann D, Berthelot J-M. A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther 2009, 11:R185. 10.1186/ar2877, 3003529, 20003278.
27. Stolina M, Schett G, Dwyer D, Vonderfecht S, Middleton S, Duryea D, Pacheco E, Van G, Bolon B, Feige U, Zack D, Kostenuik P. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. Arthritis Res Ther 2009, 11:R187. 10.1186/ar2879, 3003514, 20003323.
28. Neumann T, Oelzner P, Petrow PK, Thoss K, Hein G, Stein G, Bräuer R. Osteoprotegerin reduces the loss of periarticular bone mass in primary and secondary spongiosa but does not influence inflammation in rat antigen-induced arthritis. Inflamm Res 2006, 55:32-39. 10.1007/s00011-005-0005-5, 16429254.
29. Byrne FR, Morony S, Warmington K, Geng Z, Brown HL, Flores SA, Fiorino M, Yin SL, Hill D, Porkess V, Duryea D, Pretorius JK, Adamu S, Manoukian R, Manuokian R, Danilenko DM, Sarosi I, Lacey DL, Kostenuik PJ, Senaldi G. CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut 2005, 54:78-86. 10.1136/gut.2003.035113, 1774360, 15591508.